Praluent vs Lisinopril Head-to-Head Efficacy: What the Evidence Actually Shows

No Direct Head-to-Head Trial Exists

Praluent and lisinopril have never been compared in a randomized controlled trial. That absence is not a gap in the literature, it reflects the fact that these two drugs address different risk factors in the same broad cardiovascular disease spectrum. Comparing them directly would be like comparing a statin to a beta-blocker: both reduce cardiovascular events, but through mechanisms with essentially no mechanistic overlap.

Why the Comparison Still Matters Clinically

Prescribers and patients do, in practice, face a resource or adherence trade-off. A patient on five or six chronic medications may ask whether adding alirocumab at roughly $500 per month provides more benefit than optimizing their lisinopril dose or adding a second antihypertensive. That is a legitimate clinical question, even if no trial has answered it head-to-head.

Answering it requires understanding what each drug actually does in outcome trials, then mapping those data onto individual patient risk profiles. The sections below build that comparison systematically from primary trial evidence.

Mechanism Matters Before You Compare Outcomes

Alirocumab is a fully human monoclonal antibody that binds PCSK9, a serine protease that degrades LDL receptors on hepatocytes. Blocking PCSK9 keeps more LDL receptors available on the liver surface, which pulls circulating LDL-C out of plasma. The FDA approved alirocumab in July 2015 for adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease requiring additional LDL lowering beyond statins. Full prescribing information is available at the FDA.

Lisinopril blocks angiotensin-converting enzyme, which prevents conversion of angiotensin I to angiotensin II. Less angiotensin II means less vasoconstriction and less aldosterone release, so both preload and afterload drop. The drug also reduces bradykinin breakdown, which contributes to both its antihypertensive effect and its well-known cough side effect. The FDA-approved labeling for lisinopril covers its full indication list.

ODYSSEY OUTCOMES: What Alirocumab Actually Proved

ODYSSEY OUTCOMES enrolled 18,924 patients who had experienced an acute coronary syndrome one to twelve months before randomization. All participants were already on high-intensity or maximum-tolerated statin therapy. The trial ran a median of 2.8 years and compared alirocumab 75 mg or 150 mg subcutaneously every two weeks against placebo. The full results were published in the New England Journal of Medicine in 2018.

Primary Endpoint Results

The primary composite endpoint was coronary heart disease death, nonfatal MI, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization. Alirocumab reduced that composite by 15% relative to placebo (hazard ratio 0.85, 95% CI 0.78 to 0.93, P<0.001). The number needed to treat over 3 years was approximately 63 patients to prevent one primary endpoint event.

LDL-C fell from a mean baseline of 87 mg/dL to a mean on-treatment level of 53 mg/dL in the alirocumab group, representing a 54% reduction from baseline. Patients in the placebo arm had essentially flat LDL levels throughout the trial.

Mortality Signal in the Pre-Specified Subgroup

A pre-specified subgroup analysis showed that patients entering the trial with baseline LDL-C at or above 100 mg/dL derived a statistically significant all-cause mortality benefit: hazard ratio 0.71 (95% CI 0.56 to 0.90) in that subgroup. This mortality signal was not present in patients with baseline LDL-C below 80 mg/dL. This subgroup analysis was reported within the primary NEJM publication.

Safety Profile in ODYSSEY

Injection-site reactions occurred in 3.8% of alirocumab patients versus 2.1% in placebo. Neurocognitive events were numerically balanced between arms. Alirocumab did not increase diabetes incidence, a clinically meaningful contrast with high-intensity statins that increase new-onset diabetes risk by approximately 10 to 12%.

ALLHAT: What Lisinopril Actually Proved

The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial enrolled 33,357 participants age 55 or older with hypertension and at least one additional coronary heart disease risk factor. ALLHAT compared lisinopril, amlodipine, and doxazosin against chlorthalidone as the reference arm. The primary outcome was combined fatal coronary heart disease or nonfatal MI. The primary ALLHAT results were published in JAMA in 2002.

Primary Endpoint: Equivalence to Chlorthalidone

Lisinopril and chlorthalidone produced statistically equivalent rates of the primary outcome. Fatal CHD or nonfatal MI occurred in 11.4% of lisinopril patients versus 11.5% of chlorthalidone patients over a mean 4.9 years of follow-up (RR 1.00, 95% CI 0.91 to 1.08). Lisinopril was not inferior to the thiazide-like diuretic on the primary endpoint.

Where Lisinopril Underperformed

Lisinopril produced higher rates of stroke than chlorthalidone in ALLHAT. The stroke relative risk was 1.15 (95% CI 1.02 to 1.30), corresponding to a 15% higher relative stroke rate. This finding drove guideline-level debate about whether thiazide-like diuretics should remain first-line for most hypertensive patients, particularly Black Americans, who showed an even larger stroke difference in that subgroup. The ALLHAT authors addressed race-stratified results in the same JAMA paper.

What ALLHAT Does and Does Not Tell Us

ALLHAT compared antihypertensive drug classes within the same mechanism category: all arms lowered blood pressure. The trial does not answer whether lowering blood pressure adds more CV benefit than lowering LDL in a statin-era patient with established ASCVD. That question requires indirect comparison across trials, which is what the next section attempts.

Cross-Trial Indirect Comparison: LDL Lowering vs Blood Pressure Lowering

Because no head-to-head trial exists, the most rigorous approach is to look at how much each drug reduces residual cardiovascular risk in patients who are already on standard-of-care background therapy.

The Residual Risk Framework

In ODYSSEY OUTCOMES, all participants were already on high-intensity statins. Alirocumab produced an additional 15% relative MACE reduction on top of statin therapy. That is the marginal benefit of further LDL lowering in a post-ACS population with controlled but still-elevated LDL.

In ALLHAT, the comparators were all active antihypertensives. Lisinopril produced equivalent primary outcomes to chlorthalidone, meaning its marginal benefit over untreated hypertension was similar to that of the diuretic comparator, not zero. The 2003 JNC 7 guidelines cited ALLHAT extensively when concluding that most hypertensive patients benefit from blood-pressure lowering regardless of which first-line agent is used.

Absolute Risk Reduction: Numbers Side by Side

Placing both trials on an absolute-risk-reduction basis helps clarify the comparison despite different populations and follow-up durations.

In ODYSSEY OUTCOMES (median 2.8 years, post-ACS population): alirocumab reduced absolute MACE risk by approximately 1.6 percentage points over placebo in the overall trial population.

In large blood-pressure-lowering meta-analyses, a 10 mmHg systolic reduction reduces major cardiovascular events by approximately 20% across a broad hypertensive population. A 2016 Lancet meta-analysis of 123 trials (N=613,815) confirmed that finding, with consistent effects across baseline blood pressure, age, sex, and comorbidities. Lisinopril at 10 to 40 mg typically achieves 8 to 12 mmHg systolic reduction in office measurements.

The absolute benefit of either drug depends heavily on baseline absolute risk. A 70-year-old post-ACS patient with LDL of 110 mg/dL on a statin gains more from alirocumab. A 58-year-old with new hypertension and no prior MI gains more from reliable blood pressure control, where lisinopril is a reasonable first-line choice, especially with concurrent diabetes or microalbuminuria.

Head-to-Head Verdict Based on Current Evidence

Alirocumab and lisinopril each reduce cardiovascular events, but they do so by targeting different modifiable risk factors. In patients who have both elevated LDL on a statin and uncontrolled hypertension, the correct clinical answer is almost always both drugs, not one versus the other.

The 2022 ACC/AHA Guideline on Cardiovascular Risk Reduction states: "For patients with clinical ASCVD who are at very high risk, adding a PCSK9 inhibitor to maximally tolerated statin therapy is recommended when LDL-C remains 70 mg/dL or higher." The guideline is available through the AHA journals. Blood pressure control to below 130/80 mmHg is recommended separately, meaning the two interventions operate on parallel tracks rather than competing ones.

Dosing, Administration, and Adherence Differences

Practical differences in how these drugs are taken affect real-world efficacy as much as the pharmacology does.

Alirocumab Dosing

Alirocumab starts at 75 mg subcutaneously every two weeks, with an option to titrate to 150 mg every two weeks if LDL-C goals are not met at 4 to 8 weeks. A 300 mg monthly injection formulation is also available and was shown in the ODYSSEY CHOICE I trial (N=801) to be non-inferior to 75 mg biweekly for LDL-C lowering. Injection technique, storage at 2 to 8 degrees Celsius, and insurance prior-authorization requirements are practical barriers that lisinopril does not share. The ODYSSEY CHOICE I results are indexed on PubMed.

Lisinopril Dosing

Lisinopril tablets are taken once daily. For hypertension, the starting dose is typically 10 mg with titration to 20 to 40 mg as tolerated. For heart failure with reduced ejection fraction, target doses up to 40 mg daily are used, mirroring the ATLAS trial dose-finding data. Generic lisinopril costs approximately $4 to $10 per month at retail, making adherence cost barriers minimal compared to alirocumab. The FDA label provides the full dosing table.

Side Effect Profiles

Alirocumab's most common adverse effects are injection-site reactions and nasopharyngitis. Serious hypersensitivity reactions are rare but described in the prescribing information.

Lisinopril's most clinically important adverse effects are a dry cough (occurring in 5 to 20% of patients, more common in women and East Asian patients), hyperkalemia (particularly in CKD or concurrent RAAS therapy), and angioedema (rare but potentially life-threatening, occurring in roughly 0.1 to 0.7% of users). Angioedema risk is highest in Black patients, and this should factor into prescribing decisions.

Which Patients Benefit Most from Each Drug

Alirocumab Is the Better Choice When

The patient has established ASCVD (post-MI, post-stroke, or symptomatic PAD) and LDL-C remains at or above 70 mg/dL despite maximally tolerated statin therapy. The ODYSSEY OUTCOMES subgroup data suggest the highest absolute benefit accrues to patients with baseline LDL above 100 mg/dL. Familial hypercholesterolemia with LDL above 190 mg/dL despite statins is another primary indication. ACC/AHA blood cholesterol guidelines support this threshold-based approach.

Patients who cannot tolerate statins due to myopathy may also use alirocumab as monotherapy for primary LDL reduction, though statin intolerance should be formally confirmed before abandoning statins entirely.

Lisinopril Is the Better Choice When

The patient has hypertension as the primary modifiable risk factor and has not yet experienced an ASCVD event. Lisinopril also holds a Class I indication for all patients post-MI with reduced EF and for all patients with heart failure with reduced ejection fraction, regardless of blood pressure. The ACC/AHA Heart Failure guidelines specify RAAS inhibition as foundational therapy.

Diabetic nephropathy with microalbuminuria represents a particularly strong indication, where ACE inhibitors slow CKD progression independent of blood pressure. The HOPE trial (N=9,541) showed that ramipril (another ACE inhibitor) reduced the composite of MI, stroke, and cardiovascular death by 22% in high-risk patients, a finding that supports the broader ACE inhibitor class including lisinopril. The HOPE trial was published in the New England Journal of Medicine.

When Both Drugs Are Appropriate Together

A post-ACS patient with diabetes, an LDL of 95 mg/dL on atorvastatin 80 mg, and a blood pressure of 145/88 mmHg represents the prototypical case for concurrent use. This patient meets the ACC/AHA very-high-risk threshold for alirocumab addition and separately meets JNC guidelines for ACE inhibitor use in a diabetic hypertensive. Prescribing one instead of the other would leave a major modifiable risk factor unaddressed.

Cost, Access, and Insurance Considerations

The cost gap between these two drugs is substantial. Generic lisinopril costs approximately $4 to $10 per month. Branded Praluent carries a list price near $5,800 per year, though manufacturer copay programs can reduce out-of-pocket costs to as low as $0 for eligible commercially insured patients. Medicare Part D coverage varies by plan.

Prior authorization for PCSK9 inhibitors typically requires documentation of: (1) a qualifying diagnosis such as clinical ASCVD or familial hypercholesterolemia, (2) current high-intensity statin therapy at maximally tolerated dose, and (3) LDL-C above the plan's threshold (commonly 70 mg/dL for ASCVD or 100 mg/dL for FH) despite that statin therapy. Approval rates and timelines vary by insurer.

A 2019 cost-effectiveness analysis published in JAMA Cardiology found alirocumab cost-effective at a threshold of $150,000 per quality-adjusted life year when list price was reduced to approximately $4,500 per year, a level now achievable for many patients through negotiated or manufacturer-supported pricing. That analysis is indexed on PubMed.

Switching Between Praluent and Lisinopril: A Clinical Non-Starter

Switching from alirocumab to lisinopril, or vice versa, is not a pharmacologically meaningful substitution in most cases. These drugs act on different pathways, treat different risk factors, and are rarely substituted for one another in clinical practice. A physician might discontinue alirocumab if cost becomes prohibitive and increase statin intensity instead. A physician might discontinue lisinopril if the patient develops angioedema and switch to an ARB. Neither scenario involves replacing one drug with the other.

The only scenario where a prescriber might conceptually deprioritize one over the other is in a resource-constrained setting where the patient's absolute cardiovascular risk is driven more by one risk factor than the other. In that case, the risk factor quantification tools (Pooled Cohort Equations for 10-year ASCVD risk, plus LDL-specific risk enhancement from FH or imaging) guide the prioritization, not a blanket preference for one drug class.